Key result
Inflammasome inhibition emerges as a promising therapeutic target across atherosclerosis and heart failure.
Answers are grounded in this paper and cite their sources.
The pathogenesis of cardiovascular disease (CVD) is complex and multifactorial, and inflammation plays a central role. Inflammasomes are multimeric protein complexes that are activated in a 2-step manner in response to infection or tissue damage. Upon activation the proinflammatory cytokines, interleukins-1β and -18 are released. In the last decade, the evidence that inflammasome activation plays an important role in CVD development became stronger. We discuss the role of different inflammasomes in the pathogenesis of CVD, focusing on atherosclerosis and heart failure. This review also provides an overview of existing experimental studies and clinical trials on inflammasome inhibition as a therapeutic target in these disorders.
No takes yet. Share an insight, caveat, or question.
Olsen et al. (2021) conducted a review in Cardiovascular disease. Inflammasome inhibition was evaluated. Inflammasomes play a central role in the pathogenesis of cardiovascular disease, with emerging evidence supporting inflammasome inhibition as a therapeutic target in atherosclerosis and heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: